{"filing":{"accession_number":"0001104659-26-104940","cik":"0001551152","ticker":"ABBV","company_name":"AbbVie Inc.","form":"8-K","filing_date":"2026-09-03","report_date":"2026-09-03","primary_document":"tm2624674d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465926104940/tm2624674d1_8k.htm"},"events":[{"id":31501,"run_id":28909,"accession_number":"0001104659-26-104940","anchor_item_number":"7.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"AbbVie announced the completion of its acquisition of Apogee Therapeutics for approximately $10.9 billion ($135.11 per share in cash). This is a material acquisition disclosed under Item 7.01 (Regulation FD Disclosure) via press release. The filing explicitly states \"AbbVie Inc. (the \"Company\") issued a press release announcing the completion of its acquisition of Apogee Therapeutics, Inc.\" The transaction materially expands AbbVie's immunology pipeline with late-stage assets (zumilokibart and APG273) and is expected to impact 2026-2027 earnings per share.","company_name":"AbbVie Inc.","ticker":"ABBV","filing_date":"2026-09-03","form":"8-K","submitted_at":null,"items":[{"id":34411,"accession_number":"0001104659-26-104940","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"AbbVie announced the completion of its acquisition of Apogee Therapeutics for approximately $10.9 billion ($135.11 per share in cash). This is a material acquisition disclosed under Item 7.01 (Regulation FD Disclosure) via press release. The filing explicitly states \"AbbVie Inc. (the \"Company\") issued a press release announcing the completion of its acquisition of Apogee Therapeutics, Inc.\" The transaction materially expands AbbVie's immunology pipeline with late-stage assets (zumilokibart and APG273) and is expected to impact 2026-2027 earnings per share.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T12:48:47.321181+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34411,"accession_number":"0001104659-26-104940","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"AbbVie announced the completion of its acquisition of Apogee Therapeutics for approximately $10.9 billion ($135.11 per share in cash). This is a material acquisition disclosed under Item 7.01 (Regulation FD Disclosure) via press release. The filing explicitly states \"AbbVie Inc. (the \"Company\") issued a press release announcing the completion of its acquisition of Apogee Therapeutics, Inc.\" The transaction materially expands AbbVie's immunology pipeline with late-stage assets (zumilokibart and APG273) and is expected to impact 2026-2027 earnings per share.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T12:48:47.321181+00:00","company_name":"AbbVie Inc.","ticker":"ABBV","filing_date":"2026-09-03"}]}